Korat-Farang.com

General => Health , Education and Family => Topic started by: Roger on June 02, 2016, 06:12:07 AM

Title: Scancell cancer vaccines
Post by: Roger on June 02, 2016, 06:12:07 AM
Immunotherapy is beginning to change cancer treatments particularly in the USA and cancer will hopefully become not a 'terminal' but a chronic disease that is treatable. With respect to Scancell's science, even the word 'cure' is now being used.
Scancell have 2 platforms of science - 'Immunobody' - a vaccine injected with a small electrical charge with a device made by a USA Company, 'Ichor'. The vaccine is suitable for all and is completely non-toxic in contrast to other Immunotherapy products already in use.
The SCIB1 trial with late stage metastatic melanoma patients is completed and due to be published - the results are stunning. SCIB2 is ready for development and has up to 17 cancer targets.
The vaccines can be adapted on a 'plug and play' basis. A trial in the USA will commence soon at some of the top cancer Hospitals in the USA and managed by leading Cancer Doctors, using SCIB1 in combination with a new generation of Immunotherapy drugs, PD1 and PDL-1, known as checkpoint inhibitors which unveil cancer tumour for attack by the immune system - they have awful side effects. The immune system in such Patients is very weak BUT the Scancell vaccine stimulates that missing link enlivening the Immune system. SCIB1 also protects resected Melanoma patients from recurrence.

The second 'platform' of Scancell's science is 'Moditope' which goes into clinical trial later this year.
In the usual pre trials in humanised mice, Moditope has shown 100% yes 100% success in taking away advanced tumours. Further co-operation has started with the highly eminent Karolinska Institute in Sweden in addressing rheumatoid arthritis.

Putting myself on the line, I predict our CSO Dr Lindy Durrant, will get one maybe two Nobel prizes over the next few years. Scancell's science is stunning.

Scancell's strategy is to become a later stage development Company and achieve full value for this amazing science. The new Executive Chairman based in the USA is Dr John Chiplin and the trials involve Dr Keith Flaherty of Massachusets General and Harvard Medical School. Research is carried out in Nottingham and new offices are being opened in Oxford and San Diego.

Why am I telling you about this ? Well you know how it feels when a M8 backs a tip in the Grand National and you didn't know about it.

Seriously though, have a look at the BB for Scancell on LSE.co.uk under SCLP. The RNS section is worth digging into and the BB is currently constructive and free of trolls. And the website Scancell.co.uk.
The CEO Dr Richard Goodfellow features on youtube.

Have a look Guys and Gals - interesting as Humans to watch a little of what might one day be the end of radiotherapy, chemo and cancer as a terminal disease.

And at around 20 pence a share on the AIM market in the UK it is IMO, worth a look. DYOR.


Title: Re: Scancell cancer vaccines
Post by: Aussie on June 02, 2016, 06:25:13 AM
Roger- Very interesting information.  It will be wonderful if this treatment lives up to its expectation.
Regards
Title: Re: Scancell cancer vaccines
Post by: Coolkorat on June 02, 2016, 08:54:49 PM
Roger; there is a new article published in Nature. I've not cross-referenced with the info you have:

http://www.nature.com/articles/nature18300.epdf?referrer_access_token=NrlGoUmeL_mdhk6NKzM0odRgN0jAjWel9jnR3ZoTv0NcBQqzF1K0iNMBJ9XWZZ0hdZjr8yiAPpJpXDlwYaD_e49eTtL4CiUk-jWyPGmhWmLxgd4P2fgPFvRctHVqp-zgT3fkP0hl46Xr_yEnKFDg7g0Wi32fPuZOiN7DQ4vzv95Bkmcu8nilhM3SH_jEV1ulHqpbPdUkEuvRYgDA03ZhC2KOvMK24OFGAWSviezGdx-Icvgla69v-HiV7Wz-BnNH&tracking_referrer=www.telegraph.co.uk (http://www.nature.com/articles/nature18300.epdf?referrer_access_token=NrlGoUmeL_mdhk6NKzM0odRgN0jAjWel9jnR3ZoTv0NcBQqzF1K0iNMBJ9XWZZ0hdZjr8yiAPpJpXDlwYaD_e49eTtL4CiUk-jWyPGmhWmLxgd4P2fgPFvRctHVqp-zgT3fkP0hl46Xr_yEnKFDg7g0Wi32fPuZOiN7DQ4vzv95Bkmcu8nilhM3SH_jEV1ulHqpbPdUkEuvRYgDA03ZhC2KOvMK24OFGAWSviezGdx-Icvgla69v-HiV7Wz-BnNH&tracking_referrer=www.telegraph.co.uk)
Title: Re: Scancell cancer vaccines
Post by: Roger on June 03, 2016, 06:52:17 AM
Thanks CK - I've seen some of those.

Scancell announced a cooperation yesterday funded by a paltry £95,000 from the 'Headcase' charity for development of a vaccine for brain cancer for which there is no treatment atm. A tiny sum but a testament to the power of this 'plug and play' science.
We await news of which Pharma/Pharmas will be involved in the coming Combo trial with PD1 / PDL-1 checkpoint inhibitors which will cost $20 million at least.

The Patients on the SCIB1 melanoma trial have so far survived an average almost 4 years with no disease progression. SCIB2 is under development with several targets including I believe, triple negative breast cancer. SCIB3 prostate cancer.
SCIB4 brain cancer. Plug and play.

And the 'Moditope' promise of addressing latest stage tumours - trial imminent.

The market for cancer drugs is expected to be $150 billion dollars p.a. by 2020 - Scancell's current MC is around £50 million. Good fun to watch this.
Title: Re: Scancell cancer vaccines
Post by: Roger on June 04, 2016, 02:11:54 PM
CK I've had time now to try and read that link in detail. Have see many similar papers but this 'Nature' article is way way above my level of understanding. But I think it's pre-clinical work - interesting that Scancell's Immunobody platform is often described as a 'universal antigen delivery system'.
Of course Scancell have Patents in hand and Patents Pending.
But thanks and I'll alert the LSE BB to that one for discussion - some have a deeper grip of the subject than I do. ATB
Title: Re: Scancell cancer vaccines
Post by: Roger on September 10, 2016, 12:49:48 PM
Hi rdrokit I noticed that you were doing a course on Immunotherapy - how was it ?

Some links from the Scancell (cancer vaccines) site are below and I wonder if it may be of interest to you and others.

http://www.scancell.co.uk/products/product-pipeline
Title: Re: Scancell cancer vaccines
Post by: rdrokit on September 11, 2016, 09:30:18 AM
Hi rdrokit I noticed that you were doing a course on Immunotherapy - how was it ?

Some links from the Scancell (cancer vaccines) site are below and I wonder if it may be of interest to you and others.

http://www.scancell.co.uk/products/product-pipeline

Great course. I learned a lot about the immune system and immunology. Below are a few notes I made throughout the course.


Myeloid stem cell - produce red blood cells
Lymphoid stem cells - produce B cells & T cells.
Monocyte - largest of white blood cells. When they leave blood stream they become macrophages and found in lungs, skin and gut. Follow pathogens and destroy them with their granules.
Neutrophil - another type of white blood cell that are in high numbers in the blood stream. They use their toxic granules to destroy bacteria.
NK cells (natural killer) - react quickly -
The dendritic cell is really important for communication between white blood cells. The dendritic cells travel to lymph nodes to stimulate immune cells that are able to recognize the invading pathogen.
In the lymph nodes, T cells use their receptor to scan the dendritic cells for any pieces of foreign proteins displayed by their MHC molecules. The dendritic cells then activate the T cells and give them information on how to find the pathogens.
Helper T cells' main role is coordinating immune response, giving instructions to other types of immune cells.
The main job of cytotoxic T cells is to seek out infected cells displaying the same foreign protein on their MHC molecules and to kill them.
The other type of lymphocytes, B cells, also have specialized receptors on their surface, this time called B cell receptors. Ultimately, B cells that recognize foreign proteins or pathogens, such as bacteria, start making these in a form that can be released from the cell. These are called antibodies, and they can stick to the invading pathogens, stopping them in their tracks and marking them for destruction. B cells can also make antibodies that can stick to infected cells.
Cancer is caused by our own body's cells multiplying out of control. Cancer cells contain changes to their genetic code, their DNA, compared to normal cells. In other words, mutations-- making them subtly, but importantly, different. The fact that cancer cells are often self-sufficient in terms of growth signals, explaining how they grow outside of the normal controls. The fact that unlike normal cells, cancer cells can multiply indefinitely without stopping. They are essentially immortal.

 Immunosuppression - Research has shown that transplant recipients are at increased risk of a large number of different cancers. Some of these cancers can be caused by infectious agents, whereas others are not. The four most common cancers among transplant recipients and that occur more commonly in these individuals than in the general population are non-Hodgkin lymphoma (NHL) and cancers of the lung, kidney, and liver. NHL can be caused by Epstein-Barr virus (EBV) infection, and liver cancer by chronic infection with the hepatitis B (HBV) and hepatitis C (HCV) viruses. Lung and kidney cancers are not generally thought to be associated with infection. People with HIV/AIDS also have increased risks of cancers that are caused by infectious agents, including EBV; human herpesvirus 8, or Kaposi sarcoma-associated virus; HBV and HCV, which cause liver cancer; and human papillomavirus, which causes cervical, anal, oropharyngeal, and other cancers. HIV infection is also associated with increased risks of cancers that are not thought to be caused by infectious agents, such as lung cancer.
Graft versus tumor effect (GvT) appears after allogeneic hematopoietic stem cell transplantation (HSCT). The graft contains donor T lymphocytes that are beneficial for recipient. Donor T-cells eliminate malignant residual host T-cells (graft versus leukemia) or eliminates diverse kinds of tumors.[1] GvT might develop after recognizing tumor-specific or recipient-specific alloantigens.[99] It could lead to remission or immune control of hematologic malignancies.[2] This effect applies in myeloma and lymphoid leukemias, lymphoma, multiple myeloma and possibly breast cancer.[3] It is closely linked with graft versus host disease phenoma (GvHD). CD4+CD25+ regulatory T cells (Treg) can be used to suppress GvHD without loss of beneficial GvT effect.[4] The biology of GvT response still isn’t fully understood but it is probable that the reaction with polymorphic minor histocompatibility antigens expressed either specifically on hematopoietic cells or more widely on a number of tissue cells or tumor-associated antigens is involved.[5][6] This response is mediated largely by cytotoxic T lymphocytes (CTL) but it can be employed by natural killers (NK cells) as separate effectors, particularly in T-cell-depleted HLA-haploidentical HSCT.
The abscopal effect is a phenomenon in the treatment of metastatic cancer where localized treatment of a tumor causes not only a shrinking of the treated tumor but also a shrinking of tumors in different compartments from the treated tumor. Initially associated with single-tumor, localized radiation therapy, the term has also come to encompass other types of localized treatments such as electroporation and intra-tumoral injection of therapeutics. While this phenomenon is extremely rare, its effect on the cancer can be stunning, leading to the disappearance of malignant growths throughout the entire body. Such success has been described for a variety of cancers, including melanoma, cutaneous lymphomas, and kidney cancer.
Scientists are not certain how the abscopal effect works to eliminate cancer in patients. Studies in mice suggest that the effect may depend upon activation of the immune system. In a case study reported at Memorial Sloan-Kettering Cancer Center in New York City,[1] changes in a metastatic melanoma patient’s immune system were measured over the course of treatment. The team observed changes in tumor-directed antibody levels and immune cell populations that occurred at the time of the abscopal effect. These findings support the idea that a localized treatment may broadly stimulate the immune system to fight cancer. At this time, various immune system cells, including T-cells and dendritic cells, are believed to play a primary role.
Effects in tissues adjacent to the irradiated area are bystander effects and are not necessarily mediated by the same mechanisms as abscopal effects.
This strong immune response against a tumor even has a name-- the graft versus leukaemia effect. In rare cases, it has been reported that infection can lead to regression of cancer. Early clinicians attempted to treat tumors by injecting a combination of bacteria into them, and it was thought that the body's increased response to the bacteria also helped to fight the cancer. And today, injection of the BCG vaccine, which is usually used to vaccinate people against tuberculosis, into the bladder is used as a treatment for bladder cancer. It's still not entirely clear how this treatment works, but it seems to encourage the immune activation in the lining of the bladder, which helps to kill off the cancer cells.
Immune cells are able to migrate out of the blood and crawl through the tissues of the body ready to fight disease. And, in some cancers, it's been observed that, the more immune cells there are in the tumor, the slower the patient's cancer progresses. In fact, in some cases, the immune signature inside the tumor might be an even better indicator of how the disease will progress than traditional methods used for staging cancer. On top of this, there is a lot of evidence showing immune cell recognition of cancer cells in the laboratory, and this gives scientists much hope for the future of immunotherapy development.
So assuming the immune system does play a role in combating cancer, how then do tumour cells avoid being attacked?
Firstly, whereas infected cells can look quite different to the immune system from normal cells, often the changes in cancer cells are quite subtle so they can look pretty similar to the immune system. This means that in many cases they are inherently disguised. Despite this, by inspecting target cells closely, immune cells can potentially recognize and destroy cancer cells. However, cancer cells have a number of tactics they use to evade an immune cell poised to attack. Here, we will show you three tricks.
Firstly, cancer of cells can send direct messages in the form of small proteins called cytokines that tell the immune cells to ignore the cancer cell.
Secondly, T cells rely on special cellular MHC molecules that display bits of proteins that are located inside the cancer cell for recognition. If tumor cells lose these systems of surveillance, it effectively means they can escape close inspection.
Thirdly, cancer cells can exploit the fact that our immune cells have emergency off switches on their surface to prevent them going out of control. By pressing these off switches, cancer cells can turn off our immune cells when they are poised to attack. Finally, it's useful to think about cancer as evolving like in Darwinian evolution. Cancer cells can mutate and change over time, creating a diverse population of cells. The cancer cells that's are most adept at survival and about suppressing the immune system are the most likely to come to dominate the population. Understanding how this occurs is crucial if we are to develop novel approaches to cancer treatment.
Immunotherapy is an umbrella term that is applied to several different types of treatments, but each has the common aim to use the immune system to kill cancer cells. This might either involve rear whitening natural anti-tumor t-cells while boosting their numbers in the body or giving patients t-cells that have been reprogrammed to recognize cancer. These multiple strategies are necessary because there are so many different types of cancer, more than 200.
Understanding the immune signature inside a patient's tumor is critical if we are to develop new immunotherapy's for cancer. Immunohistochemistry, or IHC for short. And it's quite commonly used in the diagnosis to assess whether a patient is suitable for a drug therapy. Also used to examine the immune signature inside a tumor.
There are a number of B-cell tumors. So in adults, chronic lymphocytic leukaemia is the commonest leukaemia in adults. And it's usually a very slow and indolent leukaemia, which is treatable. But unfortunately, it's not curable. So there is an unmet need for those patients. In children, the commonest leukaemia is acute lymphoblastic leukaemia. And most children are cured with that leukaemia. But there are probably about 10% of children where, unfortunately, their disease hasn't been able to be cured. There are a number of other B-cell malignancies. You can get acute lymphoblastic leukaemia in adults, where the prognosis is actually quite poor. And then, most non-Hodgkin's lymphomas are B cell in origin.
Artificial T cell receptors (also known as chimeric T cell receptors, chimeric immunoreceptors, chimeric antigen receptors (CARs)) are engineered receptors, which graft an arbitrary specificity onto an immune effector cell. Typically, these receptors are used to graft the specificity of a monoclonal antibody onto a T cell; with transfer of their coding sequence facilitated by retroviral vectors. The receptors are called chimeric because they are composed of parts from different sources.
Chimeric antigen receptor (CAR) Artificial T cell receptors are under investigation as a therapy for cancer, using a technique called adoptive cell transfer.[1] T cells are removed from a patient and modified so that they express receptors specific to the particular form of cancer. The T cells, which can then recognize and kill the cancer cells, are reintroduced into the patient. Modification of T-cells sourced from donors other than the patient are also under investigation.
As you've heard previously, T cells carry a T cell receptor that enables them to recognize fragments of proteins. And some of these can recognize proteins expressed on cancer. However, sadly, in many cancer patients, such T cells a too few in number, and can't function very well, so they're unable to control the tumor. Therefore, one approach to treat these patients is to use genetic engineering to reprogram large numbers of their T cells, so that many more of them can now recognize and destroy the cancer. We can do this reprogramming of T cells in two different ways.
One approach is to introduce a gene that encodes a new T cell receptor, one that can recognize a protein on the cancer cell. The other approach is to introduce a gene that encodes what we call a chimeric antigen receptor, or CAR. A CAR is a fusion between an antibody that recognises cancer cells, and the signalling component of the T cell receptor. So when a T cell engineered to express such a CAR encounters a cancer cell, the antibody component binds to the cancer, and this will then deliver a signal to the T cell, causing it to kill that cancer cell. Key to the success of using these engineered T cells is the selection of an appropriate target protein.
Vaccines are one of the single greatest medical advances ever made, and have had a truly dramatic impact on human health. For many years now, immunologists have been trying to see if vaccines can be used to fight cancer. There are already some vaccines being used to prevent certain types of cancer from developing. One example is the human papilloma virus vaccine that is now being given to young women in many countries. This vaccine works by preventing infection with certain strains of papilloma virus that are associated with cervical cancer. We're already seeing good size of protection from cervical warts that these viruses can also cause. We hope to see that this protection extends to cancer, as well, in the future.
Title: Re: Scancell cancer vaccines
Post by: Roger on September 17, 2016, 09:04:54 AM
For rdrokit and anyone else interested - an update from Scancell .....

16 September 2016 - Scancell Holdings Plc
Final Results for the year ended 30 April 2016
Highlights
    SCIB1 continues to deliver significant survival data from the Phase 1/2 clinical trial in patients with Stage III/IV melanoma
    Currently 19 of the 20 patients with resected tumours at study entry remain alive
    Of the 16 patients who received 2-4mg doses of SCIB1
       Median observation time since entry is 49 months, a landmark survival milestone
       Only two new incidences of disease progression have been recorded since December 2013
    Of the four patients who received 8mg doses of SCIB1
       Median observation time since entry is 18 months
       None have progressed and none have died
 As announced on 17 June 2016, treatment for the eight patients in the long-term continued dosing phase has been suspended due to the clinical trial supplies no longer being within the original specification. New SCIB1 material being manufactured to support a new study of SCIB1 in combination with a checkpoint inhibitor will also be made available to these continuation patients (subject to regulatory approval)
        Plans for the US clinical study of SCIB1 in combination with a checkpoint inhibitor remain on track, enrolment expected to commence in Q3 2017
        The final Clinical Study Report will be issued later this year and will support our US IND submission·         

Continued progress made in development of lead product, Modi-1, from Moditope® platform.   Enrolment for first-in-man clinical study in triple negative breast cancer, ovarian cancer and osteosarcoma expected to commence in early 2018.

 Strategic collaboration with Karolinska Institute to explore the role of citrullination in cancer, a key mechanism underpinning the Moditope® platform

 Post Period Highlights

    Scancell’s executive management team restructured to align expertise with the strategic direction outlined in fundraising
    Dr Alan Lewis appointed to Board as Non-Executive Director
    Opening of new offices in San Diego, US and Oxford, UK to support Company’s growth plans

Dr John Chiplin, Executive Chairman of Scancell, said:
“We have continued to make significant progress in the period, both in terms of the maturing clinical data with SCIB1 and further scientific developments on both the ImmunoBody® and Moditope® platforms.  We now have a pipeline of three products across five cancer indications and clinical success with any one of these products could transform the value of the business.  The Board believes that further clinical studies could add significant value to the Company and is continuing to explore a number of funding options to ensure that the Company has the resources to progress these programmes further.
“Scancell has arrived at an exciting point in its development.  We now have the opportunity to transform the business from a small UK-based and largely scientifically-based enterprise into an international force in immuno-oncology.  We remain committed to driving this process forward in the US and elsewhere, and to realising the value that has been accumulating over recent years, both for the benefit of our shareholders and cancer patients.”

Just MHO Guys but really exciting stuff ......

 
Title: Re: Scancell cancer vaccines
Post by: Roger on September 27, 2016, 05:48:50 AM
A balanced and lengthy report has been produced by 'Hardman and Co' about the progress made and the path ahead for Scancell. An interesting comparison is made with 'Innovio' who have a fraction of Scancell's potential and a Market Capitalisation 13 times greater.

rdrokit this is Immunotherapy in action - 56 pages of it. Fascinating stuff.

http://www.hardmanandco.com/docs/default-source/company-docs/scancell-documents/26.09.16-new-frontiers-in-t-cell-activation-and-targeting.pdf

Title: Re: Scancell cancer vaccines
Post by: Roger on September 30, 2016, 02:16:31 PM
Scancell get a mention in the Investor's Chronicle today - including the Chairman's view that SCIB1 is 'the best melanoma drug in the World' and if that is right, then the Company is a gold mine. (Or five).

The Hardman report linked before lists future trials :-

SCIB1 - outstanding results already for advanced melanoma patients as a stand alone treatment and a coming trial in combo with PD1/PDL1 checkpoint inhibitors.
SCIB1 Plus - melanoma again - accessing more patient 'types'
SCIB2 - Non-small cell lung cancer

Moditope 1 - Triple negative breast cancer
                 - Ovarian cancer
                 - Osteosarcoma

To emphasise - these are just the 5 chosen targets from 2 'plug and play' vaccine platforms. Impressive targets.

Exciting times in Immuno-Oncology.

Title: Re: Scancell cancer vaccines
Post by: Roger on October 10, 2016, 02:29:30 PM
Scancell have announced a coming USA based trial for SCIB2 in treating lung cancer - specifically 'non-small-cell-lung cancer' in combination with existing drugs :-

Oncoimmunology. 2016 Jun
Published online 2016 Apr 22.

"SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade....

Checkpoint blockade has demonstrated promising antitumor responses in approximately 10–40% of patients. However, the majority of patients do not make a productive immune response to their tumors and do not respond to checkpoint blockade. These patients may benefit from an effective vaccine that stimulates high-avidity T cell responses in combination with checkpoint blockade. We have previously shown that incorporating TRP-2 and gp100 epitopes into the CDR regions of a human IgG1 DNA (ImmunoBody®: IB) results in significant tumor regression both in animal models and patients. This vaccination strategy is superior to others as it targets antigen to antigen-presenting cells and stimulates high-avidity T cell responses. To broaden the application of this vaccination strategy, 16 NY-ESO-1 epitopes, covering over 80% of HLA phenotypes, were incorporated into the IB (SCIB2). They produced higher frequency and avidity T cell responses than peptide vaccination. These T cells were of sufficient avidity to kill NY-ESO-1-expressing tumor cells, and in vivo controlled the growth of established B16-NY-ESO-1 tumors, resulting in long-term survival (35%). When SCIB2 was given in combination with Treg depletion, CTLA-4 blockade or PD-1 blockade, long-term survival from established tumors was significantly enhanced to 56, 67 and 100%, respectively. Translating these responses into the clinic by using a combination of SCIB2 vaccination and checkpoint blockade can only further improve clinical responses."

An exciting development and a massive market for this.

The 'Immunobody' platform now targeting both melanoma and lung cancer.
Title: Re: Scancell cancer vaccines
Post by: Roger on October 15, 2016, 09:05:27 AM
Heady days for Immunotherapy.

Richard Goodfellow, chief executive at drug research firm Scancell Holdings plc (LON:SCLP), tells Proactive Investors that he has high hopes for the company’s latest drug candidate, SCIB2.
“We’re very optimistic [about SCIB2] and that’s based upon new understanding around how the immune system works, to allow us to manipulate it to improve the prognosis of those patients,” he says.
Goodfellow explains that the lung cancer treatment did “all that we hoped it would in animals” and the company is now preparing SCIB2 for a Phase I clinical trial, which he says has already been designed.
Touching on the company’s lead product, SCIB1, Goodfellow says the skin cancer treatment is showing “remarkable” signs in its latest trials.
He also adds that he was “delighted” after Japanese biologist Yoshinori Ohsumi recently scooped the Nobel Prize for medicine for his work on autophagy, which links in closely with Scancell’s own research.

https://m.youtube.com/watch?v=xrTGT2L8Pwo
Title: Re: Scancell cancer vaccines
Post by: Roger on November 20, 2016, 06:02:54 AM
Slides from the recent Scancell AGM presentation giving progress with the 'Immunobody' platform and 'Moditope' - have a look at Slide 13 if you have some time - the header for Moditope says -
"overcomes immuno suppression and delivers UNPRECEDENTED Killer T- Helper cell responses". That's the action that produced 100% yes 100% anti-tumour responses (melanoma) in pre-clinical trials. Worth a read ......

http://seekingalpha.com/article/4024764-scancell-scnlf-investor-presentation-slideshow
Title: Re: Scancell cancer vaccines
Post by: Roger on January 06, 2017, 06:30:49 AM
Only 6 minutes or so - Richard Goodfellow, Scancell's CEO talking about tremendous data from the melanoma trials, synergy with 'checkpoint inhibitors' and 'memory response' giving the prospect for long term protection from cancer recurrence.

http://www.proactiveinvestors.co.uk/companies/stocktube/6674/scancell-very-optimistic-about-us-study-after-compelling-melanoma-trial-results-6674.html
Title: Re: Scancell cancer vaccines
Post by: rdrokit on January 28, 2017, 03:34:30 PM
Just read this article on Immunotherapy cancer drugs. Maybe someday soon it will be for all cancers.

http://www.bangkokpost.com/news/general/1188137/immunotherapy-cancer-drugs-cleared-by-fda

Title: Re: Scancell cancer vaccines
Post by: Roger on January 29, 2017, 07:01:16 AM
Morning rdrokit and all.
Scancell's CEO Richard Goodfellow was presenting at a 'Proactive Investors' meeting in London last week and his words were recorded on a mobile and uploaded.
I listened very carefully and commented to my colleagues on the Scancell BB as follows.
(Btw CI means 'checkpoint inhibitors' now developed by all big Pharma - they are very expensive and can have horrendous side effects whilst helping just 20-30% of Patients).

'' I sat the laptop on my ear and it WAS worth all the effort. RG opens by noting that there was almost 'standing room only' at this event.

Tremendous progress is being made by Scancell with Immunobody's ability to produce 'ultra high avidity T-cells' and Moditope as being 'incredibly exciting', a 'unique proposition' with a 'SUPERB patent position' - further described as a 'land grab' with 'actually or virtually (?) all of the land', 'to our surprise'.

CI's are dominant in Immuno-Oncology treatment atm and Immunobody is 'exquisitely suitable for a combination market' in which the figures are 'mind boggling' estimated at $50 billion p.a. Some very big deals have been done eg. the Biontech deal at $300 million for a Phase 1 asset - (an indication - not a platform ?).

Immunobody at a very low dose gives a PHENOMENAL increase in T-cells.
(Car-T .. Kite and Juno mentioned as 'very complex, very expensive and very difficult').

I was particularly interested that after talking about the 3 drugs and 5 indications, RG mentions that 'there are other things at an earlier stage not being talked about'.

Talking about the Combo trial - yes Feb 14th for the pre-IND with the FDA and submission to FDA by the end of Q1, hoping for approval Q2 and all geared up to start trial Q3 this year !

RG then uses stronger words (yes that's possible) about the Combo strategy - 'the CI / Immunobody mecahnisms are exquisitely PERFECT to combine'. Sweet Lord ! RG then describes again the full whammy of Immunobody, (my words), CI exposes, Immunobody's ultra high avidity T-Cells attack, Immunobody gives further expression of PDL-1 on the cell surface to further assist the CI action AND the exciting recent discovery of the creation of 'Immune Memory', retaining protection against re-challenge by the cancer later.

RG is pressed for time and quickly notes the 'fantastic market' for combo AND for adjuvant'.

Moving onto Moditope, which is 'uniquely patented for cancer by us'. The wonderful comment re. 100% survival of mice with heavy tumour load - 100% survival from a single injection - 'can't get mice to die'.
Further - can't tell if Moditope works with CI yet - NO model arises which allows for any increase with CI. Ouch !
And 'Moditope is scientifically fantastic'.

We ARE in active discussions NOW on partnering with many Pharma across all indications and on both platforms.

I listened and re-listened to this. Quote marks may be exact or not but E.& O.E, correct in meaning. Excuse the use of some Caps ! VGLA
''

Have a nice day All.
Title: Re: Scancell cancer vaccines
Post by: Roger on January 29, 2017, 08:07:43 AM
rdrokit - thanks for that BKK Post link.
I'm guessing that the unnamed drugs featured will be Checkpoint Inhibitors, (CI).
Maybe used in combination with chemotherapy.

I have heard a little about one melanoma drug, 'Yervoy' or Ipilumumab - in a large trial in the USA there were reports that 5 Patients died from side effects and half the Patients had to be withdrawn from treatment due to side effects. There is a Group of Yervoy lawyers in the USA dedicated to suing on Patients behalf. 20-30% of Patients benefit.

If one had Stage 3/4 melanoma and a poor prognosis, Yervoy is a step forward over nothing at all.

Scancell's Immunobody and Moditope are still relatively unknown.

You saw the 2016 Nobel for Medicine went to Yoshinori Ohsumi for 'discoveries of mechanisms for autophagy'. I am told, (though it's beyond my understanding), this is central to Prof. Lindy Durrant's work at Scancell. ATB
Title: Re: Scancell cancer vaccines
Post by: Roger on February 01, 2017, 05:45:06 PM
No comment - have a look ?

http://www.proactiveinvestors.co.uk/companies/stocktube/6826/scancell-boss-very-excited-about-collaboration-deal-with-leading-us-lung-cancer-foundation-6826.html
Title: Re: Scancell cancer vaccines
Post by: rdrokit on February 01, 2017, 05:50:12 PM
No comment - have a look ?

http://www.proactiveinvestors.co.uk/companies/stocktube/6826/scancell-boss-very-excited-about-collaboration-deal-with-leading-us-lung-cancer-foundation-6826.html

Looks promising. Might be time to invest some money in Scancell Holdings.
Title: Re: Scancell cancer vaccines
Post by: Roger on February 01, 2017, 06:14:26 PM
rdrokit. I've been in this 5 years or more.
Scancell have 2 'plug and play' platforms.

Immunobody has 95% of Melanoma stage 3 and 4 Patients alive - some for 5 years. And a combo trial with CI next. And a non small cell lung cancer trial to start in the USA.

Moditope has trials starting with ovarian cancer, osteosarcoma and triple negative breast cancer. Our Prof. Lindy was dancing around the Lab when she found Moditope. Pre-clinical survival with heavy tumour load - 100%. Nobels for her - any bets ?

Don't mean to be a bore but you know how you get told off, when a horse wins - why didn't you tell me ?

Just for the cynics - I've got nothing to gain. Just sharing.

DYOR but read more at Scancell.co.uk or LSE.co.uk moniker SCLP

If you have been abroad more than 2 years there's no CGT I understand and you can buy/sell with online trading if you have a UK Bank Account.

14.75 pence - ridiculously cheap IMVHO. ATB

Title: Re: Scancell cancer vaccines
Post by: Roger on March 20, 2017, 03:14:28 PM
This week - the 'Immuno-Oncology Summit Europe'.
From a Scancell announcement today :-
''Prof. Lindy Durrant, Ph.D., Chief Scientific Officer of Scancell and Professor of Cancer Immunotherapy, University of Nottingham, will chair the session entitled: "Combining Checkpoint Inhibitors with Other Modalities" on Thursday 23 March 2017. Prof. Durrant is also featured as a presenter in this session and will deliver a presentation entitled: "Combinations of Novel Vaccines with Checkpoint Inhibitors".

ImmunoBody® utilises both cross- and direct-presentation to increase T-cell avidity by 100 fold.  In Phase 1/2 trials, it induced T-cell responses, tumour regression and long term survival. In combination with checkpoint inhibitors, it induced 100% tumour regression in established models. Phase 2 trials of ImmunoBody® vaccines in combination with checkpoint inhibitors in melanoma and non-small cell lung cancer are being planned.

Moditope® stimulates powerful anti-tumour T-cell responses against neo-epitopes produced by enzymes induced by cellular stress. First-in-man clinical studies for breast cancer, ovarian cancer and osteosarcoma are anticipated to commence in 2018.''

Why is the above Science important ?
ATM there is a massive investment by Pharma in Checkpoint Inhibitors which help up to 30% of Patients a little and are very toxic. There have been further expectations for I.O. in Combos, but the 'let-down' is perceived to have set in :-
 No startling results from Combos based on PD-1 and PDL-1
 Additional toxicities apparent with relapses a growing concern.
 Ongoing mono therapy results with CI are not encouraging for further Combos and something is needed to 'shake up the landscape'.

Go Scancell go ! For more - LSE.co.uk and SCLP for Scancell
Title: Re: Scancell cancer vaccines
Post by: Roger on June 26, 2017, 03:37:11 PM
The European Patent Office has now granted Patent on Scancell's DNA vaccine platform, 'Immunobody', to add to Patents already in USA, Japan and Australia. Immunobody (SCIB1) has targeted Stage 3/4 Patients with advanced melanoma and many in that trial are alive after 5 years or more. The next trial (SCIB2) will be in combo with Merck's 'Keytruda', a PD-1 checkpoint inhibitor, to tackle 85% of lung cancer Patients, NSCLC.

An eminent Poster on the Scancell BB, (Boomorbust) recently reminded us :-
''As we know, Scancell have shown in preclinical research that the combination of ImmunoBody and anti PD-1 increased response rates and resulted in 85% long term survival for SCIB1/PD-1 and 100% for SCIB2/PD1 and it is PD-1 that will be combined with SCIB1 in the forthcoming trial. Of course the potential market for combinations gets bigger with each FDA/EMA approval for new cancer targets.''

http://www.lse.co.uk/share-regulatory-news.asp?shareprice=SCLP&ArticleCode=6r1f0jfw&ArticleHeadline=DNA_ImmunoBody_Patent_Granted_in_Europe

Scancell's application for a Patent on 'Moditope', their second platform is under consideration but it has been suggested that a 'land grab' of this science too, is likely. Moditope addresses advanced cancer tumours without assistance of PD-1 or any other treatment. In pre-clinical work, the cancer has been halted in almost 100% of cases.

(Such research is always carried out on 'humanised mice' - Scancell's CEO was recently quoted as saying, ''We can't get the mice to die !'' such have been the outstanding indications).

Clinical trials of Moditope begin soon - the first targets are ovarian cancer, triple negative breast cancer and osteosarcoma.

I've invested in this over the last 6 years at an average cost of 20 pence per share. Jigger me the shares are now 10-11 pence which is a bargain IMO. (SCLP peaked once at 62 pence). When Pharmaworld wakes up, a price of many pounds is possible.
DYOR.  All good fun !
Title: Re: Scancell cancer vaccines
Post by: enrico on June 26, 2017, 03:46:16 PM
type up,  the secrets of underground medicine ? by andrew brad lemley ? it will make your eyes pop ?       E.F.M.
Title: Re: Scancell cancer vaccines
Post by: Roger on June 26, 2017, 04:22:45 PM
Hi Enrico. Yes I've seen that stuff. Thanks.

The CSO of Scancell, Prof. Lindy Durrant was one of the Chairs at the recent annual meeting of ASCO, the American Society for Clinical Oncology, the largest meeting of Oncologists in the World with 30,000 attending. Prof. Keith Flaherty an Associate Prof. at Harvard Medical School etc etc etc will be running the SCIB2 trial on lung cancer - he is widely repected as being among the top Oncologists in the World.

This is innovative science - have a look at it on www.scancell.co.uk
Title: Re: Scancell cancer vaccines
Post by: Coolkorat on June 26, 2017, 04:29:54 PM
Scancell is flagged as a 'Strong Buy' on This Is Money (see http://investing.thisismoney.co.uk/quote/SCLP (http://investing.thisismoney.co.uk/quote/SCLP))

Current price = 10.63p. Broker target price = 68.00p. If the shares achieved this it would be an increase of 540%!

Roger; how are you buying your shares? There are a number of online trading platforms but all come with operational costs and someone wanting to 'take a punt' may find the admin and trading costs make the process difficult. I am not familiar with any issues for a resident of Thailand (a) opening an account with a (presumably UK) trading platform and (b) supplying the client ID info that is likely to be required.

It may be possible to create a syndicate for a handfull of friends interested in small individual investments centred on an individual with an existing trading account, and the paperwork and logistics would be relatively straightforward, but again I am not sure of the legalities.
Title: Re: Scancell cancer vaccines
Post by: Roger on June 26, 2017, 04:51:49 PM
CK nice to see you around.
Panmure Gordon are Scancell's Brokers and their valuation is 79 pence.

$1 billion for Scancell's science would be about £3 a share.
$1 billion would be peanuts for the science they have - each Immunobody target and each Moditope target is worth a fortune. The market for Cancer Immunotherapy is predicted to be £70 billion p.a. worldwide in 10 years time.
In the USA where our Chairman is based, Biotechs can attract massive values.

I purchase through my online Halifax account which has a share trading facility. It's much easier to buy on the AIM market through a UK Bank/Broker account.

Have a look at the recent 'Hardman Report' listed under RNS on lse.co.uk / SCLP

Thanks for your interest and ATB
Title: Re: Scancell cancer vaccines
Post by: Roger on June 26, 2017, 08:42:45 PM
And here it is ! In the good ole DT  ;)

http://www.telegraph.co.uk/business/2017/06/26/pioneering-british-firm-wins-patent-cancer-vaccines-technology/

Found this on the LSE Forum - can't find it on the DT website yet.

''In earlier pre-clinical trials on animals, Scancell found that when it re-challenged subjects with tumour cells after SCIB1 treatment this resulted in 100pc survival, indicating a powerful memory response. Industry insiders believe the fierce global race among pharma conglomerates to become IO market leaders make even small firms with limited clinical data such as Scancell a takeover target.

Scancell’s Immunobody patent lasts for 20 years and guarantees European competitors cannot copy or use the same scientific platform, protecting its future chances of success. The award follows similar patent protections granted to Scancell in the US, Australia and Japan.

Dr Richard Goodfellow, chief executive of Scancell, said: “The addition of this key European patent for DNA ImmunoBody significantly bolsters our global intellectual property portfolio as we position the company for future growth.”


Good news for many Patients one day, one hopes.


Title: Re: Scancell cancer vaccines
Post by: Coolkorat on June 26, 2017, 09:12:16 PM
Hi Roger

Seems worth a few £100's: almost like a charitable punt. The more support for the shares, the greater the investment in the research!

There are a number of ways to buy, this is one example: http://www.hl.co.uk/partners/search/buy-shares?theSource=PCGD4&Override=1&adg=G+FSG45+BSA+B&gclid=Cj0KEQjw4cLKBRCZmNTvyovvj-4BEiQAl_sgQsdppBbhIRVBfW96dH-tOarqnjz4eTQQzrBnRHIoilAaAuSb8P8HAQ (http://www.hl.co.uk/partners/search/buy-shares?theSource=PCGD4&Override=1&adg=G+FSG45+BSA+B&gclid=Cj0KEQjw4cLKBRCZmNTvyovvj-4BEiQAl_sgQsdppBbhIRVBfW96dH-tOarqnjz4eTQQzrBnRHIoilAaAuSb8P8HAQ)
Title: Re: Scancell cancer vaccines
Post by: Roger on August 19, 2017, 06:51:27 AM
Nice to see my ailing punt on Scancell getting some publicity. In yesterday's FT, this very lightweight review appeared. In the same number of words, MUCH MUCH more could have been said. Never mind, at least the FT know Scancell exist !

August 18, 2017 1:44 pm by Sarah Neville, Global Pharmaceuticals Editor, FT

Scancell Holdings

Aim-listed Scancell, which has a market capitalisation of about £34m, has developed two technologies that have allowed it to create vaccines to treat cancers through harnessing the immune system to overcome a tumour’s defences against detection and destruction.

The first, called ImmunoBody, enables the company to generate DNA vaccines that stimulate anti-tumour T-cells. The first product to emerge from ImmunoBody is a vaccine for the treatment of melanoma. Richard Goodfellow, chief executive, says this has shown “outstanding survival data”, with eight of the patients treated in early stage clinical trials having reached the five-year survival mark.

Its second platform, Moditope, targets advanced or hard-to-treat cancers. Enrolment for the first human clinical studies for this are expected to begin next year.

Hardman & Co, a consultancy, says that with two differentiated platforms that could be applied to many types of cancer, “Scancell’s products will become part of the overall immunotherapy segment of the market, which is clearly a multibillion-dollar opportunity”.

On Friday the company’s share price was about 10p — down from 18p a year ago.

Noting that at one point the company’s market cap had been about £100m, Mr Goodfellow says “growth and valuation of companies like ours is not a linear process” as it tends to depend on the announcement of breakthroughs. When Scancell revealed the discovery of its most recent technology, Moditope, “everyone wanted to buy the shares, and in a thinly-traded market it went up from 5p to 60p in the space of a few months”.


Watch this space - MMmmm I've been doing that for 6 years now !
Title: Re: Scancell cancer vaccines
Post by: Roger on December 14, 2017, 03:15:45 PM
Cancer Research UK, the World's largest cancer Charity, are taking Scancell's second Immunobody vaccine under their wing for development. In pre-clinical trials, SCIB 2 was targeted at NSCLC (non small cell lung cancer) which is 85% of all lung cancer cases.

The shares are up just 20 % after an hours trading. The full announcement :-

''Cancer Research UK to progress SCIB2 into a Phase 1/2 study for patients with a range of solid tumours . . . .

Scancell Holdings PLC, a developer of novel immunotherapies for the treatment of cancer, and Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research, are pleased to announce that they have entered into a Clinical Development Partnership to develop Scancell’s ImmunoBody® vaccine, SCIB2, for the treatment of patients with solid tumours, including non-small cell lung cancer (NSCLC).

Scancell’s ImmunoBody® immunotherapy platform activates the body’s immune system by enhancing the uptake and presentation of cancer antigens to help target and eliminate cancer cells. SCIB2, Scancell’s second ImmunoBody® therapy, targets an antigen called NY-ESO-1, which is expressed on a range of solid tumours, including NSCLC and oesophageal, ovarian, bladder and prostate cancers, as well as neuroblastoma, melanoma and sarcoma.

Under the terms of the Clinical Development Partnership, Cancer Research UK will fund and sponsor a UK-based Phase 1/2 clinical trial of SCIB2 in combination with a checkpoint inhibitor in patients with solid tumours, focusing on NSCLC in the first instance. The charity’s Centre for Drug Development (CDD) will be responsible for manufacturing the clinical trial supplies of SCIB2, conducting pre-clinical testing, sponsoring and managing the clinical trial, including the clinical trial timelines.

Following completion of the Phase 1/2 clinical trial, Scancell will have the option to acquire the rights to the data to support further development of SCIB2 itself. If Scancell elects not to exercise the option, Cancer Research UK will retain the right to take the SCIB2 programme forward in all indications.

Professor Lindy Durrant, Chief Scientific Officer of Scancell, commented: “We are delighted to announce this partnership with Cancer Research UK, which is a significant endorsement for our ImmunoBody® technology. The charity’s world-renowned expertise will no doubt be invaluable as we progress SCIB2 through the clinic. In pre-clinical studies, we have shown that a combination of SCIB2 and checkpoint inhibition produces enhanced tumour destruction and significantly longer survival times than when either treatment was used alone. We believe SCIB2 has the potential to provide a much needed treatment option for patients suffering from a range of common solid tumours.”

Dr Nigel Blackburn, Cancer Research UK’s director of drug development, said: “We’re excited to be giving our extensive expertise and experience in drug development to move this immunotherapy treatment into the clinic.

This collaboration will ensure that this innovative vaccine reaches patients sooner and could bring about urgently needed improvements for some cancers which can be hard to treat, including lung cancer – a disease where survival rates remain stubbornly low.”

 
Title: Re: Scancell cancer vaccines
Post by: Roger on December 14, 2017, 04:18:15 PM
Copied courtesy of 'Boom' in the Scancell chatroom :-

''Well worth having another look at the SCIB2 poster on Scancell's website (link below).

For any newbies looking in, CRUK will carry out a trial of Scancell's lung cancer vaccine SCIB2 in combination with a checkpoint inhibitor. Checkpoint inhibitors are the immunotherapy drugs that you will have read about in the press. They represent a major breakthrough in the fight against cancer but only work in about 20% to 30% of patients so the race is on to find a combination treatment that will increase the response rate.

Results of Scancell's preclinical research, testing SCIB2 in combination with both CTLA4 (Yervoy) and PD-1 (Keytruda/Opdivo) are shown in the poster. I assume that the CRUK trial will be in combination with an anti PD-1, or possibly even PD-L1. You don't need to understand all of the detail on the poster, just look at section 9 and the conclusion:-

"Anti PD-1 Ab and SCIB2 alone delays tumour growth with long term survival of more than 50%, this is further enhanced to 100% of survival when these modalities are combined"

"When SCIB2 is given in combination with Treg depletion, CTLA-4 blockade or PD-1 blockade, long term survival from established tumours is significantly enhanced to 64, 67 and 100% respectively. "

Also worth remembering that SCIB2 isn't restricted by HLA-A2 subtype, it's effective in immune subtypes of over 90% of the population.

http://www.scancell.co.uk/file-manager/scientific-papers/pivac-scib2-poster.pdf

It will be very exciting to see if these results can be replicated in the clinic and great news that the Company will manage to achieve that via non-dilutive funding without giving away any of the IP.''
Title: Re: Scancell cancer vaccines
Post by: Roger on December 15, 2017, 05:14:20 AM
Worth a look if you have interest and time  . .  ;D

https://twitter.com/scancellpharma
Title: Re: Scancell cancer vaccines
Post by: Roger on December 15, 2017, 08:26:15 AM
Sorry if it's boring - my last post on this for now :-

My good Pal, 'Prof. Inanaco' (of Pak nam Pran), posts yesterday :-
''Indeed the link that boom posted for SCIB2 was in the B16 cancer which is a melanoma which can also express the antigens NY_ESO-1 - appreciate that its not one variant of the epitope NY-ESO-1 in this instance it was 16 - so ...... NY-ESO-1 antigen such as lung, oesophageal, gastric, ovarian and bladder cancers. ImmunoBody® vaccines for prostate, liver and colorectal cancer have also been further advanced - making a total of 9 targets so far if you include scib1 in melanoma. Correction 10, brain cancer.''

My investment is still at a loss  ??? But not for long  ;)
Title: Re: Scancell cancer vaccines
Post by: Alfie on December 15, 2017, 09:06:56 AM
What's your particular interest in Scancell, Roger?

My investment is still at a loss  ??? But not for long  ;)

Only a financial interest? Shares in Scancell?
Title: Re: Scancell cancer vaccines
Post by: Roger on December 15, 2017, 02:18:38 PM
Hi Alfie. Yes I have a bucketful of shares in Scancell - it's a significant sum for me. I've been in for 7 years. IMHO the potential is stunning - not reflected in the share price yet.  ???
Title: Re: Scancell cancer vaccines
Post by: Alfie on December 16, 2017, 02:12:28 PM
Mmm. If you bought them at 5 pounds a share, you're doing OK. If you bought them at 75 pounds a share, you should be drinking very heavily as the sky seems to be falling in.

Hopefully they will come up with something soon that will boost their price.
Title: Re: Scancell cancer vaccines
Post by: Roger on December 16, 2017, 03:07:01 PM
UUmmm that's pence Alfie.
The share is 12.75 pence atm and my average is around 18 pence.
When the AIM market gets what is going on here, £5 a share is more than possible.
Maybe more. Hopefully.

Title: Re: Scancell cancer vaccines
Post by: Alfie on December 16, 2017, 03:36:58 PM
Ah, OK, pence. My mistake. But the basics remain the same. If you bought them at 5 pence a share, you're doing OK. If you bought them at 75 pence a share, they've lost about 83% of their value. If you bought them at 18p a share, they've only lost about 30% of their value. Fingers crossed!
Title: Re: Scancell cancer vaccines
Post by: Roger on February 10, 2018, 04:26:58 PM
Just an update for anyone interested - Scancell's 2nd platform - Moditope 3
In a nutshell, 144 teams entered for CRUK's Grand Challenge - up to £20 million research grants.
Scancell are on the shortlist of 10. Their topic for the challenge will be Modi3 and Scancell's Prof Lindy Durrant, will lead a team of 15 eminent Oncologist/Scientists in preparing the paper in cooperation with Genentech, (a major Biotech owned by Roche), BioNTech in Germany who are using Modi to adapt CAR-T type therapy, and ISA Pharma of Germany.

Pundits say that Moditope, taking away 100% of 'heavy tumour load' in pre-clinical work, can be an industry in itself. Share price 12 pence !


''Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, is proud to announce that an international, multi-disciplinary team of the leading cancer immunotherapy scientists in Europe and the US, led by Prof. Lindy Durrant, Chief Scientific Officer of Scancell, and in partnership with Genentech, BioNtech and ISA pharmaceuticals1, has been shortlisted to the final stages of Cancer Research UK's Grand Challenge2 - an ambitious series of £20 million global grants tackling some of the toughest questions in cancer research.  The team will collaborate on a project entitled "Project Blueprint: Eradicating established tumours with unique cancer vaccines".

Project Blueprint aims to eliminate tumours by treating patients with specific vaccines.  Prof. Lindy Durrant will lead an international world-class team to investigate the full potential of the tumour vaccine concept by building blueprints for an effective therapy for patients with most types of cancer.  The project focus will be on head and neck cancer, glioblastoma, lung, and pancreatic cancer - all of which currently have a poor prognosis - in which treatment with Modi-3, a product generated from Scancell's Moditope® platform will be assessed alongside vaccines targeting new mutations within individual patients' tumours
.''

Prof LG Durrant, University of Nottingham. Scancell Ltd., Nottingham
Prof Sahin, TRON, Mainz BioNTech, Mainz
Prof Melief, University of Leiden, ISA pharmaceuticals, Leiden
Prof Mellman, Genentech, South San Francisco
Prof Cerundulo, University of Oxford
Prof Balachandran, Memorial Sloan Kettering Cancer Center, New York
Icahn School of Medicine at Mount Sinai, New York
Prof de Vries, Radboud University, Nijmegen
Prof Platten, German Cancer Research Center, Heidelberg
University Hospital Mannheim Heidelberg University
Prof Rammensee, Eberhard-Karls University Tuebingen
Dr Benham, University of Durham
Prof Ottensmeier, University of Southampton
Prof Jaeger, National Center for Tumor Diseases University Medical Center Heidelberg
German Cancer Research Center, Heidelberg
Prof Pandurangan, La Jolla Institute for Allergy & Immunology
Prof Mehanna, University of Birmingham
Title: Re: Scancell cancer vaccines
Post by: Roger on February 10, 2018, 04:32:43 PM
More good news for Scancell - the Moditope platform is to be granted Patent in a major land grab of their Intellectual Property . . .

''Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, notes that European Patent Office has announced its intention to grant Scancell's application for a European patent for its Moditope® immunotherapy platform.

This case is key to the protection of the Company's pipeline of Moditope® vaccines for the treatment of cancer and will provide commercial exclusivity in all major European territories including: Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Sweden and Turkey.  Counterparts to this patent have been filed in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US.

Cliff Holloway, Chief Executive Officer of Scancell, commented:
"By confirming its intention to grant this patent application, the European Patent Office has continued to uphold the validity of Scancell's expanding patent estate.  This is a key case for the Company as we progress development of our Moditope® platform and provides further protection for Scancell's innovative cancer vaccine technologies.
"
Title: Re: Scancell cancer vaccines
Post by: rdrokit on February 10, 2018, 05:46:49 PM
Looks promising. Time will tell.
Title: Re: Scancell cancer vaccines
Post by: Roger on February 14, 2018, 04:05:34 AM
Yes RDRO - promising indeed and tick tock . . . . . . .
Here's more from CRUK about the 'Grand Challenge' :-

http://www.cancerresearchuk.org/funding-for-researchers/how-we-deliver-research/grand-challenge-award/shortlistedteamdurrant
Title: Re: Scancell cancer vaccines
Post by: Roger on February 15, 2018, 07:39:25 PM
Some words from little me in another place . .
If you have the time, watch the interview in this link.
You can buy shares at around 13 pence - who knows where the SP is going - ''in the near to short term''.

''Massive congratulations to our coming Nobel Prize winner, Prof. Durrant and a million pats on the back for Dr Goodfellow, who has farmed these fields with devotion and the greatest skill and persistence IMO. We all get a little bit older so a Happy Non Exec life to RG.

Dr Holloway looks to me, to be the right Guy to take SCLP forward now. An impressiive unprompted and clear performance from him. A long wait for us LTH, but following the growth of this incredible science, has been a rabbit chase. Tick tock
. . . . . . .

http://www.proactiveinvestors.co.uk/companies/stocktube/8748/new-scancell-chief-sets-out-his-vision-to-commercialise-groundbreaking-cancer-treatments-8748.html
Title: Re: Scancell cancer vaccines
Post by: Roger on February 17, 2018, 05:43:38 AM
Daily news from Scancell atm. An extensive Presentation yesterday at Calculus Capital - Prof. Lindy Durrant and Prof. Poulam Patel. Some really interesting graphics - just for anyone interested.

https://www.scancell.co.uk/file-manager/PDFs/scancell-presentation-feb18v2.pdf

DYOR and GL.
Title: Re: Scancell cancer vaccines
Post by: rdrokit on March 01, 2018, 12:03:16 PM
Roger,
Just read this article. Looks promising.

https://www.nih.gov/news-events/nih-research-matters/injection-prompts-mouse-immune-system-destroy-tumors
Title: Re: Scancell cancer vaccines
Post by: Roger on March 01, 2018, 01:18:57 PM
Thanks RDRO. Yes very interesting for an early study.

Get a load of this from a recent Scancell presentation at the Royal Society of Medicine:-

https://m.youtube.com/watch?v=zogJ2CCmOxY

It's 28 well worthwhile minutes, but if you scroll through at 9 minutes, you'll see the lovely Prof. Lindy Durrant talking about the science. Fantastic Lady. Fantastic science.

ATB
Title: Re: Scancell cancer vaccines
Post by: rdrokit on March 01, 2018, 02:59:46 PM
Roger,
Very informative. I would think if they make a big breakthrough some big pharmaceutical company would buy them out.
Title: Re: Scancell cancer vaccines
Post by: Roger on March 02, 2018, 04:43:20 AM
RDRO the BB view is that Scancell are pursuing an 'Arm Holdings' strategy - licensing out the Intellectual Property to Pharma. (similar strategy to Arms H, recently sold for £23 billion).

An unedited version of the Presentation at Royal Society of medicine has become available.

https://www.youtube.com/watch?v=CXyPYib5JWc

Listen at 29 minutes 30 seconds, Prof. Lindy says, 'my aim is to cure all cancers'.

Amazing - IMO it looks like that might be on the way. 14 pence LOL.

Title: Re: Nobel Prize for medicine
Post by: Roger on October 02, 2018, 08:15:31 AM
A first for 'Immunotherapy' - the Nobel Prize has been awarded for the science behind 'checkpoint inhibitors' - it's been found that 'CI' can help up to 30% of Patients BUT at considerable cost and with sometimes awful side effects.

Scancell's 'Immunobody' vaccine in pre-clinical trial in combo with CI, achieved 90% efficacy. Scancell's SCIB1 combo trial shortly to start in the USA and the UK, will have an 'Investigator' in Allison's ''University of Texas MD Anderson Cancer Center''.

With my shares lumping around on 10.75 pence each - maybe the sentiment is about to change. From the Guardian:-

''James Allison and Tasuku Honjo will share the 9m Swedish kronor (£775,000) prize, announced by the Nobel assembly at the Karolinska Institute in Stockholm'' . . . . .

and . .

“Over the last decade, work from both these Nobel prize winners has led to the development in the clinic of a new class of therapies – so-called checkpoint inhibitor therapies – that are transforming the management of haematological and solid tumours,” he said. “A decade ago, metastatic melanoma was largely incurable. Thanks to work from Allison and Honjo, patients now have real hope, with over a third of patients deriving long-term benefit and even cures from such therapies.”

https://www.theguardian.com/science/2018/oct/01/james-p-allison-and-tasuku-honjo-win-nobel-prize-for-medicine
Title: Re: Scancell cancer vaccines
Post by: Roger on November 21, 2018, 07:17:35 AM
Dr Cliff Holloway - CEO of Scancell - presenting at a recent Investor Forum :-

https://www.youtube.com/watch?v=nKd_cDot6cw

Have a look at Page 7 - Modi-1 - 100% response.

I believe I am right in saying that Cancer Research UK is the largest cancer charity in the World - they have taken Scancell's SCIB2 for lung cancer into their development facilities. Also Scancell are one of 10 finalists for the CRUK's Grand Challenge - 21 of the top experts in the World in the presentation team. the prize - up to £20 million.

Current Share price is 9 pence, possible value £'s 1,3,5,9 - who knows ? Other Companies with a scrap of this science are valued at many Billions. Don't say I didn't tell you. ATB
Title: Re: Scancell cancer vaccines
Post by: dereklev on November 21, 2018, 07:49:58 AM
Dr Cliff Holloway - CEO of Scancell - presenting at a recent Investor Forum :-

https://www.youtube.com/watch?v=nKd_cDot6cw

Have a look at Page 7 - Modi-1 - 100% response.

I believe I am right in saying that Cancer Research UK is the largest cancer charity in the World - they have taken Scancell's SCIB2 for lung cancer into their development facilities. Also Scancell are one of 10 finalists for the CRUK's Grand Challenge - 21 of the top experts in the World in the presentation team. the prize - up to £20 million.

Current Share price is 9 pence, possible value £'s 1,3,5,9 - who knows ? Other Companies with a scrap of this science are valued at many Billions. Don't say I didn't tell you. ATB

With the slow but steady flow of countries legalising medical marijuana there will be no need for a pharmaceutical cure,

Even Thailand has legalised its use.

Title: Re: Scancell cancer vaccines
Post by: Roger on November 21, 2018, 02:44:53 PM
Hello Derek, I don't think that marijuana has been identified as a possible cure for cancer.

Here's a bit more for you :-

https://www.youtube.com/watch?v=CXyPYib5JWc
Title: Re: Scancell cancer vaccines
Post by: Roger on November 22, 2018, 05:57:33 AM
Now, as for cannabis and cancer, I read quite a few links on Google and whilst there is some evidence that marijuana can slow progress of cancer cells, there's also some evidence it can speed them up. With the market for cancer immunotherapy due to reach £100 billion in the next few years, do you really think that Pharma would ignore marijuana as a potential cure if there was any credible evidence ?

I have seen several suggestions that marijuana can help with some cancer symptoms such as nausea, pain, food intake. Good.

The American Cancer Society comments here :-

https://www.cancer.org/treatment/treatments-and-side-effects/complementary-and-alternative-medicine/marijuana-and-cancer.html

Again - please post politely  :)
Title: Re: Scancell cancer vaccines
Post by: dereklev on November 22, 2018, 06:16:10 AM
You made both these posts which  is true!!!

Hello Derek, I don't think that marijuana has been identified as a possible cure for cancer.

Now, as for cannabis and cancer, I read quite a few links on Google and whilst there is some evidence that marijuana can slow progress of cancer cells, there's also some evidence it can speed them up. With the market for cancer immunotherapy due to reach £100 billion in the next few years, do you really think that Pharma would ignore marijuana as a potential cure if there was any credible evidence ?
Title: Re: Scancell cancer vaccines
Post by: Roger on November 22, 2018, 07:10:10 AM
Derek with respect - both are true.

There is a difference between a 'cure' for cancer and 'relief' from it's symptoms. Marijuana can help sometimes with relief from symptoms and one day, who knows ?

Re. the development of a cancer - ''marijuana can slow progress of cancer cells, there's also some evidence it can speed them up''.

https://www.cancer.org/treatment/treatments-and-side-effects/complementary-and-alternative-medicine/marijuana-and-cancer.html

And your opening comment, ''With the slow but steady flow of countries legalising medical marijuana there will be no need for a pharmaceutical cure''. Sorry that's just not true. The whole Pharma World is looking for a cure and have found checkpoint inhibitors and CAR-T therapies with cancer vaccines coming through.
Title: Re: Scancell cancer vaccines
Post by: dereklev on November 22, 2018, 07:26:26 AM
Derek with respect - both are true.

There is a difference between a 'cure' for cancer and 'relief' from it's symptoms. Marijuana can help sometimes with relief from symptoms and one day, who knows ?

Re. the development of a cancer - ''marijuana can slow progress of cancer cells, there's also some evidence it can speed them up''.

https://www.cancer.org/treatment/treatments-and-side-effects/complementary-and-alternative-medicine/marijuana-and-cancer.html

And your opening comment, ''With the slow but steady flow of countries legalising medical marijuana there will be no need for a pharmaceutical cure''. Sorry that's just not true. The whole Pharma World is looking for a cure and have found checkpoint inhibitors and CAR-T therapies with cancer vaccines coming through.

Here is a link to a link about Big Pharma and Marijuana...

https://www.google.co.th/search?q=Big+Pharma+and+Marijuana&oq=Big+Pharma+and+Marijuana&aqs=chrome..69i57.20116j1j7&sourceid=chrome&ie=UTF-8
Title: Re: Scancell cancer vaccines
Post by: Roger on November 22, 2018, 07:46:00 AM
Sorry Derek. The first article in your link - Pfizer observe ''our work in this area was confined to the Lab, never tested in Patients and eventually discontinued''.

The next -''Most common problems that can be treated with cannabis include:    Parkinson’s disease   Post-Traumatic Stress Disorder (PTSD)      Seizure disorders      Mood disorders
Pain disorders      Degenerative neurological disorders      Multiple sclerosis''

No one else seems to be mentioning marijuana as a potential 'cure' for cancer. But 'm' might help relieve some symptoms.
Title: Re: Scancell cancer vaccines
Post by: dereklev on November 22, 2018, 08:30:52 AM
Sorry Derek. The first article in your link - Pfizer observe ''our work in this area was confined to the Lab, never tested in Patients and eventually discontinued''.

The next -''Most common problems that can be treated with cannabis include:    Parkinson’s disease   Post-Traumatic Stress Disorder (PTSD)      Seizure disorders      Mood disorders
Pain disorders      Degenerative neurological disorders      Multiple sclerosis''

No one else seems to be mentioning marijuana as a potential 'cure' for cancer. But 'm' might help relieve some symptoms.

I'll bow to your vastly superior knowledge ::)
Title: Re: Scancell cancer vaccines
Post by: Roger on November 22, 2018, 09:09:20 AM
Sorry Derek. Bowing ain't wot it's about. Just the facts I hope.

I'm not being 'know all' but I've been reading about this science for 7 years now ! And reading comments on the BB, sometimes more than a hundred a day.

I still don't understand the science which is WAY OUT  ???   If you have time, watch Professor Lindy Durrant of Scancell - at 14mins 58 secs.

https://www.youtube.com/watch?v=CXyPYib5JWc

This is her team for the CRUK Grand Challenge award, potentially £20 million :-
Prof LG Durrant University of Nottingham, Scancell Ltd., Nottingham
Prof Sahin,TRON, Mainz BioNTech, Mainz
Prof Melief, University of Leiden ISA pharmaceuticals, Leiden
Prof Mellman, Genentech, South San Francisco
Prof Cerundulo, University of Oxford
Prof Balachandran, Memorial Sloan Kettering Cancer Center, New York
Icahn School of Medicine at Mount Sinai, New York
Prof de Vries, Radboud University, Nijmegen
Prof Platten, German Cancer Research Center, Mannheim Heidelberg University
Prof Rammense, Eberhard-Karls University Tuebingen
Dr Benham, University of Durham
Prof Ottensmeier, University of Southampton
Prof Jaeger, National Center for Tumor Diseases German Cancer Research Center, Heidelberg
Prof Pandurangan, La Jolla Institute for Allergy & Immunology
Prof Mehanna, University of Birmingham

CRUK have already taken the SCIB2 vaccine for a lung cancer trial.

Another trial for malignant melanoma will be underway soon - Chief Investigator, Prof Keith Flaherty, one of the USA's top cancer surgeons. The latest submission to the FDA was 2600 pages long !

Have a look at this rather wooden presentation from the CEO - however the slides on screen are amazing  https://www.youtube.com/watch?v=nKd_cDot6cw

And the thread has been read 1761 times. Nice day to you ATB



Title: Re: Scancell cancer vaccines
Post by: Roger on December 08, 2018, 03:12:13 PM
Hopefully this IS of interest to one or two K-F's - (I see the thread has 2000 views or more). In a few years time, cancer treatment is going to be very different and hopefully, much more effective. This particular trail-blazing Company, Scancell, have engaged 'Trinity Delta' as Advisors and they have written an impressive report. Share price around 8 pence atm.  ;)

http://docs.wixstatic.com/ugd/07354c_b3b393d919ad412aabb576db17467d6a.pdf

The next news from Scancell is likely to be an Award from CRUK's 'Grand Challenge'.
Title: Re: Scancell cancer vaccines
Post by: Roger on March 27, 2019, 03:06:24 PM
As I see my average 17p per share investment in Scancell at 5.6p, here's what we have in this Company now.

Stolen from my colleagues Crumbs and Ray Pointer, in the LSE chatroom, here's a list - bearing in mind that when the SCIB1 melanoma vaccine was still in Phase 2 trial, on the morning that the 'serendipitous' discovery of Moditope was announced, the price soared to 60 pence or more inside a few hours :-

''I know it's been done before but a comparison of the MCAP at its peak some time after Moditope was announced

GBP 100 million post Moditope announcement with :-

No SCIB1 trial results
Moditope announced . . . . . . . .

**************************************

Now GBP 23 million with :-

Immunobody
SCIB1 outstanding results
Patents complete
SCIB1 combo trial starts soon (we hope)
SCIB2 combo trial funded by CRUK (probably starting next year)
Glioblastoma vaccine collaboration

Moditope
Patents almost complete for citrullinated targets
Modi trial starts soon (we hope)
Addition of amplivant to Moditope
Modi2 may now be in development
Collaboration with Biontech for 2 targets on TCR going well
Appointment of TCR specialist scientist
Collaboration with Karolinska

Glycans
Patent process underway

Scientific endorsements
Peer review of SCIB1 trial
SCIB1 combo trial managed by Keith Flaherty
CRUK funding of SCIB2 combo trial
Project blueprint team members
BionTech collaboration
Karolinska collaboration
Lindy winning Waldenström award

And finally, (Prof.) Lindy is asking the question :-


http://www.portlandpresspublishing.com/sites/default/files/biochemist/Biochemist%20Immunology%20issue/BioFEB19Web_Choudhury%29.pdf  ''

Plenty of news to come. Meantime . . . as my old Pal Spargo says in Cornwall, ''can't help poverty Boy".